Synairgen plc (LON:SNG – Get Free Report) was down 12.1% during mid-day trading on Thursday . The company traded as low as GBX 4.31 ($0.06) and last traded at GBX 4.31 ($0.06). Approximately 94,904 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 349,617 shares. The stock had previously closed at GBX 4.91 ($0.06).
Synairgen Stock Performance
The firm’s fifty day moving average is GBX 3.83 and its 200 day moving average is GBX 5.04. The firm has a market capitalization of £8.60 million, a price-to-earnings ratio of -163.50 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Synairgen
- What is Put Option Volume?
- Broadcom’s Targeted Upside Just Keeps Getting Better
- Are Penny Stocks a Good Fit for Your Portfolio?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- About the Markup Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
